Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma
Latest Information Update: 23 Jan 2024
Price :
$35 *
At a glance
- Drugs Mogamulizumab (Primary) ; Vorinostat
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Registrational; Therapeutic Use
- Acronyms MAVORIC
- Sponsors Kyowa Kirin; Kyowa Kirin International; Kyowa Kirin Pharmaceutical Development
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of retrospective, post Hoc analysis of Health-Related Quality of Life in Cutaneous T-Cell Lymphoma, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to a Kyowa Kirin International media release, company announced health-related quality of life (HRQL) findings from a post hoc analysis of the this trial presented at the 65th annual American Society of Hematology meeting in San Diego, CA